Related Experiment Videos
OraQuick ADVANCE Rapid HIV-1/2 antibody test
Steven J Reynolds1, Jérémie Muwonga
1National Institute of Allergy and Infectious Diseases, National Institutes of Health, ICER Program Uganda, 2190 Kampala Place, Washington, DC 20521, USA. sjr@jhmi.edu
Expert Review of Molecular Diagnostics
|September 7, 2004
Summary
Rapid HIV antibody tests, like the OraQuick ADVANCE, offer accurate and simple HIV diagnosis. This FDA-approved test is valuable for expanding HIV testing and treatment access globally.
Area of Science:
- Medical Diagnostics
- Infectious Diseases
- Public Health
Background:
- Rapid HIV antibody tests are crucial for timely diagnosis and management of HIV infection.
- The OraQuick ADVANCE Rapid HIV-1/2 antibody test has gained FDA approval and CLIA waiver.
- The test is validated for oral mucosal transudate, whole blood, and plasma samples.
Purpose of the Study:
- To evaluate the performance characteristics of the OraQuick ADVANCE Rapid HIV-1/2 antibody test.
- To highlight the clinical utility and applications of this rapid HIV test.
Main Methods:
- Clinical evaluation of the OraQuick ADVANCE Rapid HIV-1/2 antibody test.
- Assessment of test sensitivity and specificity across different sample types.
Main Results:
- The OraQuick ADVANCE Rapid HIV-1/2 antibody test demonstrated high sensitivity and specificity.
- The test's simplicity and accuracy support its use in diverse clinical settings.
Conclusions:
- The OraQuick ADVANCE Rapid HIV-1/2 antibody test is a reliable tool for HIV diagnosis.
- This rapid test enhances opportunities for voluntary counseling and testing.
- It serves as a vital tool for scaling up antiretroviral therapy in resource-limited settings.